SequelSEC

ABVC BIOPHARMA, INC. ABVC

Pharmaceutical Preparations · CIK 0001173313 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$509.79K
Fiscal year ended 2024-09-30
Operating income
-$4.51M
Fiscal year ended 2024-09-30
Free cash flow
Unavailable
Fiscal year ended 2024-09-30

ABVC BIOPHARMA, INC. (ABVC) reported revenue of $509.79K and net income of -$4.55M for the fiscal year ended 2024-09-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from ABVC BIOPHARMA, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

ABVC BIOPHARMA, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-09-30
Revenue$509.79K
Cost of revenue$139.97K
Gross profit$369.82K
Operating income-$4.51M
Net income-$4.55M
Research & development$219.48K
Weighted-average diluted sharesUnavailable
Pretax income-$5.10M
Income tax expenseUnavailable
Diluted EPS$-0.12
Selling, general & administrative$3.48M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

ABVC BIOPHARMA, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-09-30
Cash & equivalents$137.34K
Total assets$7.78M
Current assets$2.17M
Total liabilities$6.44M
Current liabilities$6.25M
Total equity incl. NCI$1.34M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$1.53K
GoodwillUnavailable
Long-term debtUnavailable
Accounts payableUnavailable

Cash flow

ABVC BIOPHARMA, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-09-30
Operating cash flow-$1.54M
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flow$1.68M
Net change in cash-$351.06K
Stock-based compensation$1.19M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

ABVC BIOPHARMA, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-09-30
Free cash flowUnavailable
Gross margin72.5%
Operating margin-885.2%
FCF marginUnavailable
SBC / revenue232.7%
Current ratio0.35x
Revenue YoY growth-31.0%
Net margin-893.4%
R&D / revenue43.1%
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ABVC in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-18View SEC filing
10-Q/A · Filed 2026-03-03View SEC filing
10-K · Filed 2026-03-03View SEC filing
10-Q · Filed 2025-11-03View SEC filing
10-Q · Filed 2025-08-13View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ACAD ACET ACRS ACRV ACTU

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.